JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2012, 61(4):144-149

Mitochondrial enzyme ABAD and its role in the development and treatment of Alzheimer's disease

Ondřej Benek1, Kamil Musílek2,*, Kamil Kuča3
1 Univerzita obrany, Fakulta vojenského zdravotnictví, Katedra toxikologie a Centrum pokročilých studií, Hradec Králové
2 Univerzita Hradec Králové, Přírodovědecká fakulta, Katedra chemie, Hradec Králové, Česká republika
3 Fakultní nemocnice, Hradec Králové

The amyloid-ß peptide (Aß) has been associated with Alzheimer's disease (AD) for some time. The original amyloid cascade hypothesis declared that the insoluble extracellular plaques were responsible for main Aß toxicity. Nowadays, this hypothesis is outdated and soluble intracellular Aß forms and their effects within the cell have come into the centre of attention. There are many intracellular proteins interacting with Aß including the mitochondrial enzyme amyloid-binding alcohol dehydrogenase (ABAD). The interaction between ABAD and Aß impairs mitochondrial functions and ultimately results in cell death. In this review, current findings concerning the enzyme ABAD are summarized. Its role in AD development and its interaction with Aß as a potential therapeutic target are discussed.

Keywords: Alzheimer's disease; amyloid-ß peptide; mitochondrial dysfunction; amyloid-binding alcohol dehydrogenase; frentizole

Received: May 15, 2012; Accepted: July 2, 2012; Published: April 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Benek O, Musílek K, Kuča K. Mitochondrial enzyme ABAD and its role in the development and treatment of Alzheimer's disease. Čes. slov. farm. 2012;61(4):144-149.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Price D. L., Sisodia S. S.:Mutant genes in familial Alzheimer's disease and transgenic models. Annu. Rev. Neurosci. 1998; 21, 479-505. Go to original source... Go to PubMed...
    2. Selkoe D. J. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature. 1999; 399(Suppl), A23-31. Go to original source... Go to PubMed...
    3. Reddy P. H., Mani G., Park B. S., et al. Differential loss of synaptic proteins in Alzheimer's disease: implications for synaptic dysfunction. J. Alzheimers Dis. 2005; 7(2), 103-117; discussion 173-180. Go to original source... Go to PubMed...
    4. Golde T. E. Inflammation takes on Alzheimer disease. Nat. Med. 2002; 8(9), 936-938. Go to original source... Go to PubMed...
    5. Reddy P. H., McWeeney S., Park B. S. et al. Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease. Hum. Mol. Genet. 2004; 13(12), 1225-1240. Go to original source... Go to PubMed...
    6. Reddy P. H., Beal M. F. Are mitochondria critical in the pathogenesis of Alzheimer's disease? Brain Res. Brain Res. Rev. 2005; 49(3), 618-632. Go to original source... Go to PubMed...
    7. Reddy P. H., McWeeney S. Mapping cellular transcriptosomes in autopsied Alzheimer's disease subjects and relevant animal models. Neurobiol. Aging. 2006; 27(8), 1060-1077. Go to original source... Go to PubMed...
    8. Keller J. N. Age-related neuropathology, cognitive decline, and Alzheimer's disease. Ageing Res. Rev. 2006; 5(1), 1-13. Go to original source... Go to PubMed...
    9. Selkoe D. J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 2001; 81(2), 741-766. Go to original source... Go to PubMed...
    10. Hardy J. A., Higgins G. A. Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992; 256(5054), 184-185. Go to original source... Go to PubMed...
    11. Dahlgren K. N., Manelli A. M., Stine W. B. Jr., Baker L. K., Krafft G. A., LaDu M. J. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J. Biol. Chem. 2002; 277(35), 32046-32053. Go to original source... Go to PubMed...
    12. Gouras G. K., Tsai J., Naslund J. et al. Intraneuronal Abeta42 accumulation in human brain. Am. J. Pathol. 2000; 156(1), 15-20. Go to original source... Go to PubMed...
    13. Wirths O., Multhaup G., Bayer T. A. A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide-the first step of a fatal cascade. J. Neurochem. 2004; 91(3), 513-520. Go to original source... Go to PubMed...
    14. Tillement L., Lecanu L., Papadopoulos V. Alzheimer's disease: effects of ß-amyloid on mitochondria. Mitochondrion. 2011; 11(1), 13-21. Go to original source... Go to PubMed...
    15. Hirai K., Aliev G., Nunomura A. et al. Mitochondrial abnormalities in Alzheimer's disease. J. Neurosci. 2001; 21(9), 3017-3023. Go to original source... Go to PubMed...
    16. Bubber P., Haroutunian V., Fisch G., Blass J. P., Gibson G. E. Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann. Neurol. 2005; 57(5), 695-703. Go to original source... Go to PubMed...
    17. Butterfield D. A., Drake J., Pocernich C., Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol Med. 2001; 7(12), 548-554. Go to original source... Go to PubMed...
    18. LaFerla F. M. Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nat. Rev. Neurosci. 2002; 3(11), 862-872. Go to original source... Go to PubMed...
    19. Manczak M., Park B. S., Jung Y., Reddy P. H. Differential expression of oxidative phosphorylation genes in patients with Alzheimer's disease: implications for early mitochondrial dysfunction and oxidative damage. Neuromolecular Med. 2004; 5(2), 147-162. Go to original source... Go to PubMed...
    20. Fernández-Vizarra P., Fernández A. P., Castro-Blanco S. et al. Intra- and extracellular Abeta and PHF in clinically evaluated cases of Alzheimer's disease. Histol. Histopathol. 2004; 19(3), 823-844.
    21. Lustbader J. W., Cirilli M., Lin C. et al. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science. 2004; 304(5669), 448-452. Go to original source... Go to PubMed...
    22. Kim H. S., Lee J. H., Lee J. P. et al. Amyloid beta peptide induces cytochrome C release from isolated mitochondria. Neuroreport. 2002; 13(15), 1989-1993. Go to original source... Go to PubMed...
    23. Aleardi A. M., Benard G., Augereau O. et al. Gradual alteration of mitochondrial structure and function by beta-amyloids: importance of membrane viscosity changes, energy deprivation, reactive oxygen species production, and cytochrome c release. J. Bioenerg. Biomembr. 2005; 37(4), 207-225. Go to original source... Go to PubMed...
    24. Moreira P. I., Santos M. S., Moreno A., Rego A. C., Oliveira C. Effect of amyloid beta-peptide on permeability transition pore: a comparative study. J. Neurosci. Res. 2002; 69(2), 257-267. Go to original source... Go to PubMed...
    25. Hansson Petersen C. A., Alikhani N., Behbahani H. et al. The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proc. Natl. Acad. Sci. USA 2008; 105(35), 13145-13150. Go to original source... Go to PubMed...
    26. Area-Gomez E., de Groof A. J. C., Boldogh I., et al. Presenilins are enriched in endoplasmic reticulum membranes associated with mitochondria. Am. J. Pathol. 2009; 175(5), 1810-1816. Go to original source... Go to PubMed...
    27. Muirhead K. E. A., Borger E., Aitken L., Conway S. J., Gunn-Moore F. J. The consequences of mitochondrial amyloid beta-peptide in Alzheimer's disease. Biochem. J. 2010; 426(3), 255-270. Go to original source... Go to PubMed...
    28. Yan S. D., Fu J., Soto C. et al. An intracellular protein that binds amyloid-beta peptide and mediates neurotoxicity in Alzheimer's disease. Nature. 1997; 389(6652), 689-695. Go to original source... Go to PubMed...
    29. Du H., Guo L., Fang F. et al. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat. Med. 2008; 14(10), 1097-1105. Go to original source... Go to PubMed...
    30. Verdier Y., Földi I., Sergeant N. et al. Characterization of the interaction between Abeta 1-42 and glyceraldehyde phosphodehydrogenase. J. Pept. Sci. 2008; 14(6), 755-762. Go to original source... Go to PubMed...
    31. Park H. J., Seong Y. M., Choi J. Y., Kang S., Rhim H. Alzheimer's disease-associated amyloid beta interacts with the human serine protease HtrA2/Omi. Neurosci. Lett. 2004; 357(1), 63-67. Go to original source... Go to PubMed...
    32. He X. Y., Schulz H., Yang S. Y. A human brain L-3-hydroxyacyl-coenzyme A dehydrogenase is identical to an amyloid beta-peptide-binding protein involved in Alzheimer's disease. J. Biol. Chem. 1998; 273(17), 10741-10746. Go to original source... Go to PubMed...
    33. He X. Y., Merz G., Yang Y. Z., Mehta P., Schulz H., Yang S. Y. Characterization and localization of human type10 17beta-hydroxysteroid dehydrogenase. Eur. J. Biochem. 2001; 268(18), 4899-4907. Go to original source... Go to PubMed...
    34. He X. Y., Yang Y. Z., Schulz H., Yang S. Y. Intrinsic alcohol dehydrogenase and hydroxysteroid dehydrogenase activities of human mitochondrial short-chain L-3-hydroxyacyl-CoA dehydrogenase. Biochem. J. 2000; 345(Pt 1), 139-143. Go to original source...
    35. Furuta S., Kobayashi A., Miyazawa S., Hashimoto T. Cloning and expression of cDNA for a newly identified isozyme of bovine liver 3-hydroxyacyl-CoA dehydrogenase and its import into mitochondria. Biochim. Biophys. Acta. 1997; 1350(3), 317-324. Go to original source... Go to PubMed...
    36. He X. Y., Wen G. Y., Merz G. et al. Abundant type 10 17 beta-hydroxysteroid dehydrogenase in the hippocampus of mouse Alzheimer's disease model. Brain Res. Mol. Brain Res. 2002; 99(1), 46-53. Go to original source... Go to PubMed...
    37. Ofman R., Ruiter J. P. N., Feenstra M. et al. 2-Methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency is caused by mutations in the HADH2 gene. Am. J. Hum. Genet. 2003; 72(5), 1300-1307. Go to original source... Go to PubMed...
    38. He X. Y., Merz G., Mehta P., Schulz H., Yang S. Y. Human brain short chain L-3-hydroxyacyl coenzyme A dehydrogenase is a single-domain multifunctional enzyme. Characterization of a novel 17beta-hydroxysteroid dehydrogenase. J. Biol. Chem. 1999; 274(21), 15014-15019. Go to original source... Go to PubMed...
    39. Powell A. J., Read J. A., Banfield M. J. et al. Recognition of structurally diverse substrates by type II 3-hydroxyacyl-CoA dehydrogenase (HADH II)/amyloid-beta binding alcohol dehydrogenase (ABAD). J. Mol. Biol. 2000; 303(2), 311-327. Go to original source... Go to PubMed...
    40. Du Yan S., Zhu Y., Stern E. D. et al. Amyloid beta-peptide-binding alcohol dehydrogenase is a component of the cellular response to nutritional stress. J. Biol. Chem. 2000; 275(35), 27100-27109. Go to original source...
    41. He X. Y., Wegiel J., Yang Y. Z., Pullarkat R., Schulz H., Yang S. Y. Type 10 17beta-hydroxysteroid dehydrogenase catalyzing the oxidation of steroid modulators of gamma-aminobutyric acid type A receptors. Mol. Cell. Endocrinol. 2005; 229(1-2), 111-117. Go to original source... Go to PubMed...
    42. Holzmann J., Frank P., Löffler E., Bennett K. L., Gerner C., Rossmanith W. RNase P without RNA: identification and functional reconstitution of the human mitochondrial tRNA processing enzyme. Cell. 2008; 135(3), 462-474. Go to original source... Go to PubMed...
    43. Yang S. Y., He X. Y., Miller D. Hydroxysteroid (17ß) dehydrogenase X in human health and disease. Mol. Cell. Endocrinol. 2011; 343(1-2), 1-6. Go to original source... Go to PubMed...
    44. Kissinger C. R., Rejto P. A., Pelletier L. A. et al. Crystal structure of human ABAD/HSD10 with a bound inhibitor: implications for design of Alzheimer's disease therapeutics. J. Mol. Biol. 2004; 342(3), 943-952. Go to original source... Go to PubMed...
    45. Xie Y., Deng S., Chen Z., Yan S., Landry D. W. Identification of small-molecule inhibitors of the Abeta-ABAD interaction. Bioorg. Med. Chem. Lett. 2006; 16(17), 4657-4660. Go to original source... Go to PubMed...
    46. Yan Y., Liu Y., Sorci M. et al. Surface plasmon resonance and nuclear magnetic resonance studies of ABAD-Abeta interaction. Biochemistry. 2007; 46(7), 1724-1731. Go to original source... Go to PubMed...
    47. Yan S. D., Shi Y., Zhu A. et al. Role of ERAB/L-3-hydroxyacyl-coenzyme A dehydrogenase type II activity in Abeta-induced cytotoxicity. J. Biol. Chem. 1999; 274(4), 2145-2156. Go to original source... Go to PubMed...
    48. Oppermann U. C., Salim S., Tjernberg L. O., Terenius L., Jörnvall H. Binding of amyloid beta-peptide to mitochondrial hydroxyacyl-CoA dehydrogenase (ERAB): regulation of an SDR enzyme activity with implications for apoptosis in Alzheimer's disease. FEBS Lett. 1999; 451(3), 238-242. Go to original source... Go to PubMed...
    49. Yao J., Taylor M., Davey F. et al. Interaction of amyloid binding alcohol dehydrogenase/Abeta mediates up-regulation of peroxiredoxin II in the brains of Alzheimer's disease patients and a transgenic Alzheimer's disease mouse model. Mol. Cell. Neurosci. 2007; 35(2), 377-382. Go to original source... Go to PubMed...
    50. Ren Y., Xu H. W., Davey F. et al. Endophilin I expression is increased in the brains of Alzheimer disease patients. J. Biol. Chem. 2008; 283(9), 5685-5691. Go to original source... Go to PubMed...
    51. Ramjaun A. R., Angers A., Legendre-Guillemin V., Tong X. K., McPherson P. S. Endophilin regulates JNK activation through its interaction with the germinal center kinase-like kinase. J. Biol. Chem. 2001; 276(31), 28913-28919. Go to original source... Go to PubMed...
    52. Sayre L. M., Zelasko D. A., Harris P. L., Perry G., Salomon R. G., Smith M. A. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J. Neurochem. 1997; 68(5), 2092-2097. Go to original source... Go to PubMed...
    53. Murakami Y., Ohsawa I., Kasahara T., Ohta S. Cytoprotective role of mitochondrial amyloid beta peptide-binding alcohol dehydrogenase against a cytotoxic aldehyde. Neurobiol. Aging. 2009; 30(2), 325-329. Go to original source... Go to PubMed...
    54. Dye R. V., Miller K. J., Singer E. J., Levine A. J. Hormone replacement therapy and risk for neurodegenerative diseases. Int. J. Alzheimers Dis. 2012; 2012, 258454. Go to original source... Go to PubMed...
    55. Yao J., Du H., Yan S. et al. Inhibition of Amyloid-beta (A beta) peptide-binding alcohol dehydrogenase-A beta interaction reduces a beta accumulation and improves mitochondrial function in a mouse model of Alzheimer's disease. J. Neurosci. 2011; 31(6), 2313-2320. Go to original source... Go to PubMed...
    56. Lim Y. A., Grimm A., Giese M. et al. Inhibition of the mitochondrial enzyme ABAD restores the amyloid-ß-mediated deregulation of estradiol. PLoS ONE. 2011; 6(12), e28887. Go to original source... Go to PubMed...

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.